bupropion and glp 1 Add-On to GLP-1s Yields Greater Weight Loss Clinically significant weight loss with
Description
Cochrane Database Syst Rev 2012

Report it

Exp Clin Psychopharmacol 26(2):168 Bremmer M, Hendershot C (2023) Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders
The STEP 9 trial, published in the New England Journal of Medicine in 2024, seemed to confirm this
bariatric procedure volumes declined 11.4% in 2025 reversing a two-decade growth trend as semaglutide and tirzepatide provide comparable weight loss outcomes for class I and class II obesity without surgical risk, recovery time, or nutritional deficiency complications
